EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

Validation of an Automated, End-to-End Metagenomic Sequencing Assay for Agnostic Detection of Respiratory Viruses

Nick P G Gauthier iD, Wilson Chan, Kerstin Locher iD, Duane Smailus iD, Robin Coope iD, Marthe Charles iD, Agatha Jassem iD, Jennifer Kopetzky, Samuel D Chorlton iD, Amee R Manges iD

The Journal of Infectious Diseases · 16.12.2024 · 230 (6) · e1245-e1253

DOI: 10.1093/infdis/jiae226 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 02.05.2024. Verfasst von Nick P G Gauthier und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, University of British Columbia, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Metagenomics, High-Throughput Nucleotide Sequencing, Respiratory Tract Infections, Nasopharynx. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biomedical Advanced Research and Development Authority, HHS, Department of Health and Human Services.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Current molecular diagnostics are limited in the number and type of detectable pathogens. Metagenomic next-generation sequencing (mNGS) is an emerging, and increasingly feasible, pathogen-agnostic diagnostic approach. Translational barriers prohibit the widespread adoption of this technology in clinical laboratories. We validate an end-to-end mNGS assay for detection of respiratory viruses. Our assay is optimized to reduce turnaround time, lower cost per sample, increase throughput, and deploy secure and actionable bioinformatic results.

Methods

We validated our assay using residual nasopharyngeal swab specimens from Vancouver General Hospital (n = 359), which were reverse-transcription polymerase chain reaction positive, or negative for influenza, severe acute respiratory syndrome coronavirus 2, and respiratory syncytial virus. We quantified sample stability, assay precision, the effect of background nucleic acid levels, and analytical limits of detection. Diagnostic performance metrics were estimated.

Results

We report that our mNGS assay is highly precise and semiquantitative, with analytical limits of detection ranging from 103 to 104 copies/mL. Our assay is highly specific (100%) and sensitive (61.9% overall: 86.8%; reverse-transcription polymerase chain reaction cycle threshold < 30). Multiplexing capabilities enable processing of up to 55 specimens simultaneously on an Oxford Nanopore GridION device, with results reported within 12 hours.

Conclusions

This study report outlines the diagnostic performance and feasibility of mNGS for respiratory viral diagnostics, infection control, and public health surveillance. We addressed translational barriers to widespread mNGS adoption.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetagenomicsHigh-Throughput Nucleotide SequencingRespiratory Tract InfectionsNasopharynxHumansSensitivity and SpecificitySARS-CoV-2Molecular Diagnostic TechniquesViruses

Stichwörter der Autor:innen

metagenomicmolecular diagnosticnext-generation sequencingviral diagnostics

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, University of British Columbia, Vancouver, British Columbia, Canada.
  • School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada.
  • Division of Medical Microbiology, Vancouver General Hospital, Vancouver, British Columbia, Canada.
  • Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Canada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, British Columbia, Canada.
  • British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada.

ORCID-Profile: Nick P G Gauthier, Kerstin Locher, Duane Smailus, Robin Coope, Marthe Charles, Agatha Jassem, Samuel D Chorlton, Amee R Manges

Förderung

  • Biomedical Advanced Research and Development Authority
  • HHS
  • Department of Health and Human Services

Zitieren

APA

Gauthier, N. P. G., Chan, W., Locher, K., Smailus, D., Coope, R., Charles, M., Jassem, A., Kopetzky, J., Chorlton, S. D., & Manges, A. R. (2024). Validation of an Automated, End-to-End Metagenomic Sequencing Assay for Agnostic Detection of Respiratory Viruses. The Journal of Infectious Diseases, 230(6), e1245-e1253. https://doi.org/10.1093/infdis/jiae226

Vancouver

Gauthier NPG, Chan W, Locher K, Smailus D, Coope R, Charles M, et al. Validation of an Automated, End-to-End Metagenomic Sequencing Assay for Agnostic Detection of Respiratory Viruses. The Journal of Infectious Diseases. 2024;230(6):e1245-e1253. doi:10.1093/infdis/jiae226

BibTeX
@article{Gauthier2024,
  author = {Gauthier, Nick P G and Chan, Wilson and Locher, Kerstin and Smailus, Duane and Coope, Robin and Charles, Marthe and Jassem, Agatha and Kopetzky, Jennifer and Chorlton, Samuel D and Manges, Amee R},
  title = {Validation of an Automated, End-to-End Metagenomic Sequencing Assay for Agnostic Detection of Respiratory Viruses},
  journal = {The Journal of Infectious Diseases},
  year = {2024},
  volume = {230},
  number = {6},
  pages = {e1245--e1253},
  doi = {10.1093/infdis/jiae226}
}
Kostenlos starten →